67. 多発性嚢胞腎 Disease details / Clinical trials / Drug dev / DR info

0C23   
   Palladio Biosciences Inc.
      2022   Phase 3   EUCTR2021-003062-12-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003062-12-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003062-12-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003062-12-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Palladio Biosciences, Inc.
      2022   Phase 3   EUCTR2021-003062-12-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
15 or   
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark;
30 or   
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark;
AL01211   
   AceLink Therapeutics, Inc.
      2021   Phase 1   NCT04908462   Australia;
Aminohippurate Sodium Inj   
   University of Colorado Denver School of Medicine Barbara Davis Center
      2020   -   NCT04407481   United States;
Anti-hypertensive medications   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2003   -   NCT00067977   United States;
Antihypertensive drugs   
   Mei changlin
      2013   Phase 2   NCT01932450   China;
BIM 23014   
   DIPAK Consortium
      2012   -   EUCTR2011-005017-37-NL   Netherlands;
Bardoxolone Metile   
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
Bardoxolone methyl   
   Reata Pharmaceuticals, Inc.
      2019   Phase 3   NCT03749447   Australia;Japan;Puerto Rico;United States;
      2019   Phase 3   JPRN-UMIN000039943   Japan,North America,Australia,Europe;
Bardoxolone methyl capsules   
   Reata Pharmaceuticals, Inc.
      2017   Phase 2   NCT03366337   United States;
Bardoxolone methyl oral capsule   
   Reata Pharmaceuticals, Inc.
      2019   Phase 3   NCT03918447   Australia;Belgium;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Bosutinib   
   Pfizer
      2010   Phase 2   NCT01233869   Australia;Canada;Czech Republic;Hungary;Italy;Korea, Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Bosutinib (anhydrous)   
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023017-65-ES   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2011   -   EUCTR2010-023017-65-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-023017-65-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023017-65-SK   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023017-65-GB   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023017-65-SE   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023017-65-PL   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023017-65-LT   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023017-65-HU   Australia;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
C03XA01   
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark;
CARDURA   
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom;
Calcineurin inhibitors maintenance   
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02134899   France;
Candesartan and Cilnidipine   
   Kyorin University
      2007   Phase 4   NCT00541853   Japan;
Candesartan plus non-CCB agents   
   Kyorin University
      2007   Phase 4   NCT00541853   Japan;
Certican   
   Novartis Pharma GmbH
      2007   -   EUCTR2006-001485-16-FR   Austria;France;Germany;
Certican Tabletten   
   Novartis Pharma GmbH
      2006   -   EUCTR2006-001485-16-DE   Austria;France;Germany;
      2006   -   EUCTR2006-001485-16-AT   Austria;France;Germany;
Cilnidipine   
   Ministry of Health, Labour and Welfare, Japan
      2009   Phase 2   NCT00890279   Japan;
Conventional therapy   
   Mario Negri Institute for Pharmacological Research
      2010   Phase 2/Phase 3   NCT01223755   Italy;
      2007   Phase 2   NCT00491517   Italy;
Curcumin   
   University of Colorado, Denver
      2015   Phase 4   NCT02494141   United States;
Emodin   
   Zhi-Hong Liu, M.D.
      2008   -   NCT00801268   China;
Equal   
   OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC
      2010   -   EUCTR2010-018401-10-IT   France;Germany;Italy;Netherlands;United Kingdom;
Everolimus   
   A. Manzoni Hospital
      2008   Phase 2/Phase 3   NCT01009957   Italy;
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02134899   France;
   Novartis Pharma GmbH
      2007   -   EUCTR2006-001485-16-FR   Austria;France;Germany;
      2006   -   EUCTR2006-001485-16-DE   Austria;France;Germany;
      2006   -   EUCTR2006-001485-16-AT   Austria;France;Germany;
   Novartis Pharmaceuticals
      2006   Phase 4   NCT00414440   Austria;France;Germany;
G1117337   
   GALAPAGOS NV
      2020   Phase 2   EUCTR2019-003521-21-IT   Belgium;Bulgaria;Czech Republic;Germany;Greece;Ireland;Italy;Netherlands;United Kingdom;
   Galapagos NV
      2020   Phase 2   EUCTR2019-003521-21-NL   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-003521-21-DE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-003521-21-CZ   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-003521-21-BE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      -   Phase 2   EUCTR2019-003521-21-ES   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
GLPG2737   
   GALAPAGOS NV
      2020   Phase 2   EUCTR2019-003521-21-IT   Belgium;Bulgaria;Czech Republic;Germany;Greece;Ireland;Italy;Netherlands;United Kingdom;
   Galapagos NV
      2020   Phase 2   NCT04578548   Belgium;Czechia;Germany;Italy;Netherlands;Poland;Spain;
      2020   Phase 2   EUCTR2019-003521-21-NL   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-003521-21-DE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-003521-21-CZ   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      2020   Phase 2   EUCTR2019-003521-21-BE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
      -   Phase 2   EUCTR2019-003521-21-ES   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain;
GZ/SAR402671   
   GENZYME CORPORATION
      2018   Phase 2   EUCTR2017-004084-12-IT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
GZ402671   
   Sanofi K.K.
      2019   Phase 2-3   JPRN-JapicCTI-184192   Japan, Asia except Japan, North America, South America, Europe, Oceania;
Genz-682452-AU   
   GENZYME CORPORATION
      2018   Phase 2   EUCTR2017-004084-12-IT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
   Genzyme Corporation
      2019   Phase 2   EUCTR2017-004084-12-NL   Argentina;Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004084-12-GB   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004084-12-AT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-PT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-DK   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-DE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-CZ   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-BE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
HCT   
   University Medical Center Groningen
      2018   Phase 2   EUCTR2017-003864-10-NL   Netherlands;
High water intake   
   Cambridge University Hospitals NHS Foundation Trust
      2016   -   NCT02933268   United Kingdom;
Hydralazine   
   University of Kansas Medical Center
      2018   Early Phase 1   NCT03423810   United States;
Hydrochlorothiazide   
   University Medical Center Groningen
      2018   Phase 2   EUCTR2017-003864-10-NL   Netherlands;
Hyperpolarized [1-13C]pyruvate   
   Aarhus University
      2022   Phase 2   EUCTR2021-002551-11-DK   Denmark;
Imidapril   
   Ministry of Health, Labour and Welfare, Japan
      2009   Phase 2   NCT00890279   Japan;
Intravenous injection autologous mesenchymal stem cells   
   Royan Institute
      2014   Phase 1   NCT02166489   Iran, Islamic Republic of;
Iohexol Inj 300 milligrams per milliliter (MG/ML)   
   University of Colorado Denver School of Medicine Barbara Davis Center
      2020   -   NCT04407481   United States;
JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)   
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy;
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)   
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy;
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)   
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy;
JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
Jinarc   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2014-001501-41-BE   Argentina;Belgium;France;Germany;Japan;United States;
      2015   Phase 3   EUCTR2014-001501-41-FR   Argentina;Belgium;France;Germany;Japan;United States;
Jinarc - Tolvaptan tablets   
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark;
Jinarc 15 mg tablets, Jinarc 45 mg tablets   
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark;
Jinarc 30 mg Tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
Jinarc 30 mg tablets, 90 mg tablets   
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark;
Jinarc 30 mg tablets, Jinarc 60 mg tablets   
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark;
Jinarc® 15mg Tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom;
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
Jinarc® 30 Tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom;
KD019 (tesevatinib)   
   Kadmon Corporation, LLC
      2012   Phase 1/Phase 2   NCT01559363   United States;
LANREOTIDE ACETATE   
   DIPAK Consortium
      2012   -   EUCTR2011-005017-37-NL   Netherlands;
Lanreotide   
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02127437   France;
   Radboud University
      2011   -   NCT01354405   Netherlands;
      2008   Phase 2/Phase 3   NCT00771888   Belgium;Netherlands;
      2007   Phase 2/Phase 3   NCT00565097   Belgium;Netherlands;
   University Medical Center Groningen
      2012   Phase 3   NCT01616927   Netherlands;
Lisinopril   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2006   Phase 3   NCT01885559   United States;
      2006   Phase 3   NCT00283686   United States;
Lixivaptan   
   Palladio Biosciences
      2022   Phase 3   NCT05208866   United States;
      2021   Phase 3   NCT04064346   Argentina;Australia;Canada;Chile;Hungary;Israel;Romania;Spain;United States;
      2020   Phase 3   NCT04152837   United States;
      2019   -   NCT03717181   United States;
      2018   Phase 2   NCT03487913   United States;
   Palladio Biosciences Inc.
      2022   Phase 3   EUCTR2021-003062-12-SK   Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003062-12-HU   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003062-12-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003062-12-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Palladio Biosciences, Inc.
      2022   Phase 3   EUCTR2021-003062-12-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
Long-acting somatostatin   
   Mario Negri Institute for Pharmacological Research
      2006   Phase 3   NCT00309283   Italy;
Losartan   
   Shanghai Changzheng Hospital
      2011   -   ChiCTR-TRC-11001282   China;
Lucrin   
   University Medical Center Groningen
      2021   Phase 2   EUCTR2020-005949-16-NL   Netherlands;
Metformin   
   Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
      2019   Phase 3   NCT03764605   Italy;
   Kyongtae Ty Bae, M.D., Ph.D.
      2016   Phase 2   NCT02656017   United States;
   University Medical Center Groningen
      2018   Phase 2   EUCTR2017-003864-10-NL   Netherlands;
   University of Colorado, Denver
      2016   Phase 2   NCT02903511   United States;
Metformin XR   
   The University of Queensland
      2022   Phase 3   NCT04939935   Australia;
Ng-monomethyl-L-arginine (drug)   
   Regional Hospital Holstebro
      2006   Phase 1   NCT00345137   -
Niacinamide   
   Alan Yu, MB, BChir
      2014   Phase 2   NCT02140814   United States;
   University of Kansas Medical Center
      2015   Phase 2   NCT02558595   United States;
OPC-41061   
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT01022424   Japan;
      2006   Phase 2   NCT00841568   Japan;
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2011   -   EUCTR2010-018401-10-NL   Afghanistan;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands;
OPC-41061 (tolvaptan)   
   Otsuka Pharmaceutical Co., Ltd.
      2007   Phase 3   JPRN-JapicCTI-070402   Japan, North America, South America, Europe, Oceania;
Octeotride   
   Federico II University
      2009   Phase 2/Phase 3   NCT02119052   -
      2009   Phase 2/Phase 3   NCT02119013   -
Octreotide   
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2011   Phase 3   EUCTR2011-000138-12-IT   Italy;
      2009   Phase 3   EUCTR2009-012376-27-IT   Italy;
      2006   Phase 3   EUCTR2005-005552-41-IT   Italy;
   Mayo Clinic
      2007   Phase 2/Phase 3   NCT00426153   United States;
Octreotide LAR   
   Mario Negri Institute for Pharmacological Research
      2018   Phase 2   NCT03541447   Italy;
Octreotide-LAR   
   Mario Negri Institute for Pharmacological Research
      2011   Phase 3   NCT01377246   Italy;
PB   
   Mayo Clinic
      2022   Phase 2   NCT05190744   United States;
PF-05208763   
   PFIZER INC.
      2011   -   EUCTR2010-023017-65-IT   Australia;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023017-65-ES   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2011   -   EUCTR2010-023017-65-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-023017-65-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023017-65-SK   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023017-65-GB   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023017-65-SE   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023017-65-PL   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023017-65-LT   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023017-65-HU   Australia;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Pasireotide LAR   
   Mayo Clinic
      2012   Phase 2   NCT01670110   United States;
Phase A Tolvaptan   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   NCT02964273   Belgium;Germany;Italy;United Kingdom;
Phase B Tolvaptan   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   NCT02964273   Belgium;Germany;Italy;United Kingdom;
Pioglitazone   
   Indiana University
      2016   Phase 2   NCT02697617   United States;
Placebo   
   Otsuka Pharmaceutical Co., Ltd.
      2007   Phase 3   JPRN-JapicCTI-070402   Japan, North America, South America, Europe, Oceania;
   Sanofi K.K.
      2019   Phase 2-3   JPRN-JapicCTI-184192   Japan, Asia except Japan, North America, South America, Europe, Oceania;
Potassium   
   Shanghai Changzheng Hospital
      2011   -   ChiCTR-TRC-11001282   China;
Pravastatin   
   University of Colorado, Denver
      2017   Phase 4   NCT03273413   United States;
      2006   Phase 3   NCT00456365   United States;
   University of Southern California
      2019   Phase 2   NCT04284657   United States;
Protein   
   Esther Meijer
      2020   -   NCT04310319   Netherlands;
RAD001   
   Novartis Pharma GmbH
      2007   -   EUCTR2006-001485-16-FR   Austria;France;Germany;
      2006   -   EUCTR2006-001485-16-DE   Austria;France;Germany;
      2006   -   EUCTR2006-001485-16-AT   Austria;France;Germany;
RAPAMUNE*100CPR RIV   
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2007   -   EUCTR2007-006557-25-IT   Italy;
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2007-005047-21-IT   Italy;
RAPAMUNE*30CPR RIV   
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2007-005047-21-IT   Italy;
      2007   Phase 2   EUCTR2006-003427-37-IT   Italy;
RGLS4326   
   Regulus Therapeutics Inc.
      2020   Phase 1   NCT04536688   United States;
RTA 402   
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
   Reata Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2018-004651-20-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004651-20-DE   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004651-20-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004651-20-CZ   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004651-20-BE   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom;United States;
Ramipril   
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2007   -   EUCTR2007-006557-25-IT   Italy;
Rapamune   
   The Cleveland Clinic
      2006   Phase 1/Phase 2   NCT00286156   United States;
Rapamune 1mg tablets   
   Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3
      2014   Phase 3   EUCTR2012-000550-60-AT   Austria;
Rapamycin   
   Yale University
      2009   Phase 2/Phase 3   NCT00920309   United States;
Renal sympathetic denervation   
   Mei changlin
      2013   Phase 2   NCT01932450   China;
SAMSCA 7.5 mg oral tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
SANDOSTATINA - LAR 20 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI   
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy;
SANDOSTATINA LAR   
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2011   Phase 3   EUCTR2011-000138-12-IT   Italy;
      2009   Phase 3   EUCTR2009-012376-27-IT   Italy;
SAR402671, GZ402671 o GZ/SAR402671   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2020-004400-34-IT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
SAR402671, GZ402671 or GZ/SAR402671   
   Genzyme Corporation
      2019   Phase 2   EUCTR2017-004084-12-NL   Argentina;Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004084-12-GB   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004084-12-AT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-PT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-DK   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-DE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-CZ   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-BE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
   Sanofi-Aventis Recherche & Développement
      2021   Phase 3   EUCTR2020-004400-34-PT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2020-004400-34-NL   Argentina;Australia;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2020-004400-34-DE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2020-004400-34-BE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
SKI-606   
   PFIZER INC.
      2011   -   EUCTR2010-023017-65-IT   Australia;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023017-65-ES   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
   Pfizer Inc.
      2011   -   EUCTR2010-023017-65-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-023017-65-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023017-65-SK   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 2   EUCTR2010-023017-65-GB   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023017-65-SE   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023017-65-PL   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023017-65-LT   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023017-65-HU   Australia;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
SODIUM PYRUVATE   
   Aarhus University
      2022   Phase 2   EUCTR2021-002551-11-DK   Denmark;
Saline   
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02127437   France;
Samsca   
   Department of Medical Research
      2015   Phase 2   EUCTR2015-001903-30-DK   Denmark;
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2011   -   EUCTR2010-018401-10-NL   Afghanistan;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark;
Samsca 15 mg tablets   
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands;
Samsca 30 mg tablets   
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands;
Sandostatin LAR   
   Radboud University Nijmegen Medical Centre
      2011   -   EUCTR2009-017849-57-NL   Netherlands;
Sandostatina LAR   
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy;
Sandostatina Lar IM Fl 20mg +2F   
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2006   Phase 3   EUCTR2005-005552-41-IT   Italy;
Sirolimus   
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2007   -   EUCTR2007-006557-25-IT   Italy;
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2007-005047-21-IT   Italy;
      2007   Phase 2   EUCTR2006-003427-37-IT   Italy;
   Mario Negri Institute for Pharmacological Research
      2010   Phase 2/Phase 3   NCT01223755   Italy;
      2007   Phase 2   NCT00491517   Italy;
   Medical University of Vienna
      2014   Phase 3   NCT02055079   Austria;
      2009   -   NCT01632605   Austria;
   Seoul National University Hospital
      2011   Phase 2/Phase 3   NCT01680250   Korea, Republic of;
   University of Zurich
      2006   Phase 3   NCT00346918   Switzerland;
Sodium citrate   
   University of Southern California
      2019   Phase 2   NCT04284657   United States;
Sodiumchloride   
   Esther Meijer
      2020   -   NCT04310319   Netherlands;
Somatuline Autogel   
   DIPAK Consortium
      2012   -   EUCTR2011-005017-37-NL   Netherlands;
Somatuline Autosolution   
   Radboud University Nijmegen Medical Centre
      2011   -   EUCTR2009-017849-57-NL   Netherlands;
Spironolactone   
   University of Colorado, Denver
      2013   Phase 3   NCT01853553   United States;
Sugar pill   
   University of Colorado, Denver
      2013   Phase 3   NCT01853553   United States;
TOL   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
TOLVAPTAN (OPC-41061)   
   Otsuka Pharmaceutical Development & Commercialization
      2016   Phase 3   EUCTR2014-001516-19-SE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-001516-19-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-001516-19-DK   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-001516-19-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001516-19-PL   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001516-19-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001516-19-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001516-19-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-001516-19-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-001516-19-FR   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-001516-19-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;United Kingdom;United States;
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom;
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
      -   Phase 3   EUCTR2020-005991-36-DE   Belgium;Germany;Italy;United Kingdom;United States;
TOLVAPTAN 15   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
TOLVAPTAN 30   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
TOLVAPTAN 45/15   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
TOLVAPTAN 60/30   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;
Telmisartan   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2006   Phase 3   NCT01885559   United States;
      2006   Phase 3   NCT00283686   United States;
Tesevatinib   
   Kadmon Corporation, LLC
      2017   Phase 2   NCT03203642   United States;
      2017   Phase 1   NCT03096080   United States;
      2015   Phase 2   NCT02616055   United States;
Tetracosactin   
   Istanbul University
      2006   -   NCT00598377   Turkey;
Tolvaptan   
   Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
      2019   Phase 3   NCT03764605   Italy;
   Department of Nephrology, Tokyo Women'
   Horie Shigeo
      2019   -   JPRN-jRCTs031180259   Japan;
   Korea Otsuka Pharmaceutical Co., Ltd.
      2019   Phase 4   NCT03949894   Korea, Republic of;
      2016   -   NCT03406286   Korea, Republic of;
   Kyorin University
      2016   -   NCT02729662   Japan;
   Kyorin University School of Medicine
      2014   Phase 4   JPRN-UMIN000015715   Japan;
   Lisbet Brandi
      2018   Phase 4   NCT03596957   Denmark;
   Mario Negri Institute for Pharmacological Research
      2018   Phase 2   NCT03541447   Italy;
   OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC
      2007   -   EUCTR2006-002768-24-IT   Denmark;France;Germany;Italy;United Kingdom;
   Otsuka Pharmaceutical Co., Ltd.
      2014   -   NCT02847624   Japan;
      2010   Phase 3   NCT01280721   Japan;
      2010   Phase 3   JPRN-JapicCTI-101362   -
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2011   -   EUCTR2010-018401-10-NL   Afghanistan;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2014-001501-41-BE   Argentina;Belgium;France;Germany;Japan;United States;
      2015   Phase 3   EUCTR2014-001501-41-FR   Argentina;Belgium;France;Germany;Japan;United States;
      2015   Phase 3   EUCTR2014-000226-38-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-000226-38-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-000226-38-FR   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-000226-38-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-000226-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   NCT02251275   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000226-38-SE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000226-38-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000226-38-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000226-38-HU   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000226-38-DK   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-000226-38-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2010   Phase 3   NCT01214421   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 2   NCT01336972   Netherlands;
      2007   Phase 3   NCT00428948   Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2005   Phase 2   NCT00413777   United States;
   Regional Hospital Holstebro
      2015   Phase 3   NCT03803124   Denmark;
      2015   Phase 2   NCT02527863   Denmark;
   s Medical University
Tolvaptan (OPC-41061)   
   Otsuka Maryland Research Institute, Inc.
      2007   Phase 3   EUCTR2006-002768-24-FR   Belgium;Denmark;France;Germany;Italy;United Kingdom;
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2021   Phase 3   NCT04786574   -
      2014   Phase 3   NCT02160145   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-002768-24-GB   Belgium;Denmark;France;Germany;Italy;United Kingdom;
      2007   -   EUCTR2006-002768-24-DK   Denmark;France;Germany;Italy;United Kingdom;
      2007   -   EUCTR2006-002768-24-DE   Denmark;France;Germany;Italy;United Kingdom;
   Otsuka Pharmaceutical Development & Commercialization. Inc.
      2007   Phase 3   EUCTR2006-002768-24-BE   Belgium;Denmark;France;Germany;Italy;United Kingdom;
Tolvaptan 15 mg Tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom;
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
Tolvaptan 15 mg tablets   
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands;
Tolvaptan 30 mg Tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom;
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
Tolvaptan 30 mg tablets   
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States;
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands;
Tolvaptan 50mg Granules   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
      -   Phase 3   EUCTR2020-005991-36-DE   Belgium;Germany;Italy;United Kingdom;United States;
Tolvaptan 7.5 mg Tablet   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom;
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom;
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Germany;Italy;United Kingdom;United States;
Tolvaptan IR   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2011   Phase 2   NCT01451827   United States;
      2010   Phase 2   NCT01210560   United States;
Tolvaptan MR   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2011   Phase 2   NCT01451827   United States;
      2010   Phase 2   NCT01210560   United States;
Tolvaptan Suspension   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2021   Phase 3   NCT04782258   -
Tolvaptan Tablets   
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2021   Phase 3   NCT04782258   -
Triptolide-Containing Formulation   
   Shanghai Changzheng Hospital
      2014   Phase 3   NCT02115659   China;
UDCA   
   Nephrology Center, Toranomon Hospital
      2014   -   JPRN-UMIN000012865   Japan;
URSOCHOL 300   
   Radboud University Nijmegen Medical Center
      2013   Phase 4   EUCTR2013-003207-19-NL   Netherlands;Spain;
Unknown   
   Radboud University Nijmegen Medical Centre
      2011   -   EUCTR2009-017849-57-NL   Netherlands;
Venglustat   
   GENZYME CORPORATION
      2018   Phase 2   EUCTR2017-004084-12-IT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
   Genzyme Corporation
      2019   Phase 2   EUCTR2017-004084-12-NL   Argentina;Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004084-12-GB   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004084-12-AT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-PT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-DK   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-DE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-CZ   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004084-12-BE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States;
   Sanofi K.K.
      2019   Phase 2-3   JPRN-JapicCTI-184192   Japan, Asia except Japan, North America, South America, Europe, Oceania;
   Tanaka Tomoyuki
      2021   Phase 3   JPRN-jRCT2031200348   Japan;United States;
Venglustat GZ/SAR402671   
   Genzyme, a Sanofi Company
      2018   Phase 1   NCT03687554   United States;
Venglustat GZ402671   
   Genzyme, a Sanofi Company
      2018   Phase 2/Phase 3   NCT03523728   Argentina;Australia;Austria;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States;
   Sanofi
      2021   Phase 3   NCT04705051   Australia;Belgium;France;Germany;Japan;Korea, Republic of;Netherlands;Romania;Spain;United States;
Venglustat malate   
   Sanofi-Aventis Recherche & Développement
      2021   Phase 3   EUCTR2020-004400-34-PT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2020-004400-34-NL   Argentina;Australia;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2020-004400-34-DE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2020-004400-34-BE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
Venglustat malato   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2020-004400-34-IT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;
Water   
   New York University School of Medicine
      2008   -   NCT00784030   United States;
   Rigshospitalet, Denmark
      2015   -   NCT02776241   Denmark;
   The Rogosin Institute
      2017   -   NCT03102632   United States;
   Tufts Medical Center
      2014   Phase 2/Phase 3   NCT02225860   United States;
   University of Cologne
      2021   -   NCT04680780   Germany;
   University of Kansas
      2008   -   NCT00759369   United States;
ZESTRIL   
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom;
ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL   
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy;